Joseph P. Schwartz

Dyax Corp. (NASDAQ: DYAX) shares have jumped 61 percent year-to-date, but are down 22 percent since April 13 when they touched a high of $29.09. Leerink’s Joseph P. Schwartz upgraded the rating on the company to Outperform, while raising the price target from $25 to $36. Reliable...

In a report published Tuesday, Leerink Swann analyst Joseph P. Schwartz reiterated an Outperform rating and $106.00 price target on Aegerion Pharmaceuticals (NASDAQ: AEGR). In the report, Leerink Swann noted, “This afternoon we spoke with AEGR management who continued to highlight its confidence...

In a report published Tuesday, Leerink Swann analyst Joseph P. Schwartz downgraded the rating on Synageva BioPharma Corp. (NASDAQ: GEVA) from Outperform to Market Perform, and lowered the price target from $66.00 to $62.00. In the report, Leerink Swann noted, “We are downgrading GEVA shares from...

In a report published Thursday, Leerink Swann analyst Joseph P. Schwartz reiterated an Outperform rating on The Medicines Company (NASDAQ: MDCO), and raised the price target from $40.00 to $42.00. In the report, Leerink Swann noted, “At today's analyst meeting, MDCO reviewed the status of its...

In a report published Wednesday, Leerink Swann analyst Joseph P. Schwartz reiterated an Outperform rating and $22.00 price target on Insmed (NASDAQ: INSM). In the report, Leerink Swann noted, “With potentially pivotal but simultaneously proof-of-concept Arikace non-tuberculous mycobacteria (NTM)...

Leerink Swann analyst Joseph P. Schwartz reiterated his Outperform rating for shares of Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) and raised the price target from $8 to $10. Swann discussed the implications of Inspire Pharmaceuticals' AzaSite product having entered into Phase II trials to treat...